Fully human anti-CD39 antibody potently inhibits ATPase activity in cancer cells via uncompetitive allosteric mechanism-Reference-Cited by-同舟云学术

Fully human anti-CD39 antibody potently inhibits ATPase activity in cancer cells via uncompetitive allosteric mechanism

Published:2020-01-01 Issue:1 Volume:12 Page:
ISSN:1942-0862
Container-title:mAbs
language:en
Short-container-title:mAbs

Author:

Spatola Bradley N.¹,Lerner Alana G.²,Wong Clifford¹,dela Cruz Tracy²³,Welch Megan²,Fung Wanchi¹,Kovalenko Maria⁴,Losenkova Karolina⁵,Yegutkin Gennady G.⁵,Beers Courtney²,Corbin John¹,Soros Vanessa B.¹

Affiliation:

1. Antibody Development, Tizona Therapeutics, South San Francisco, CA, USA

2. Immunology, Tizona Therapeutics, South San Francisco, CA, USA

3. Immunology, Trishula Therapeutics, South San Francisco, CA, USA

4. Clinical Biomarkers, AbbVie, Redwood City, CA, USA

5. MediCity Research Laboratory, University of Turku, Turku, Finland

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/19420862.2020.1838036

Reference71 articles.

1. Targeting immunosuppressive adenosine in cancer

2. Cellular function and molecular structure of ecto-nucleotidases

3. Commentary: A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment

4. Regulation of the T Cell Response by CD39

5. Adenosine 5′-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Adenosinergic Pathway in Non-Small Cell Lung Cancer;Cancers;2024-09-13

2. CD39 transforming cancer therapy by modulating tumor microenvironment;Cancer Letters;2024-08

3. Epitope Mapping of an Anti-Mouse CD39 Monoclonal Antibody Using PA Scanning and RIEDL Scanning;Monoclonal Antibodies in Immunodiagnosis and Immunotherapy;2024-04-01

4. Generation and characterization of antagonistic anti-human CD39 nanobodies;Frontiers in Immunology;2024-03-25

5. Purinergic pathways and their clinical use in the treatment of acute myeloid leukemia;Purinergic Signalling;2024-03-06